Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Research Council grant · Running

IMPACT Immuno-Modulatory Platform for Advanced CLL Therapy

Coordinator
Stichting Amsterdam Umc, Netherlands
Runs
1 October 2026 to 31 March 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101335091

What the project is doing

In the project's own words, from its summary on CORDIS.

This project aims to advance a first-in-class/best-in-disease novel trispecific T cell engager, TRIDENT-19, with improved efficacy as compared to standard CD3-based bispecifics as it overcomes tumor-associated T cell dysfunction. Multispecific antibodies (MA) enable simultaneous engagement of immune effector cells and tumor cells. Crosstalk within the tumor microenvironment frequently impairs T cell function, leading to partial and short-lived responses to CD3-engaging multispecific antibodies in cancers such as in CLL.

Based on our ERC-Consolidator funded studies (864815/BOOTCAMP), we made the exciting discovery of an alternative T-cell activating entry point that bypasses tumor-mediated T-cell dysfunction. To exploit this finding, we developed a (ERC PoC funded) trispecific T-cell engager platform to overcome limitations of CD3 engagers. This led to a lead CD19 engaging candidate, TRIDENT-19, that induces potent T cell responses against malignant B cells, outperforming a CD3-based control compound, highlighting its potential as a therapeutic candidate.

IMPACT will address key steps required to move TRIDENT-19 towards clinical readiness: 1) The optimization of the IgG1-based T cell engaging scaffold, by designing backbone variables and identifying the most efficient configuration of the TRIDENT scaffold using cell lines and primary patient-derived tumor- and T cells. 2) Investigation of different binder combinations, comparing clinically validated CD19 binders and assessing whether optimized targeting improves cytotoxic activity. 3) Evaluation of TRIDENT’s applicability to other B-cell malignancies by targeting additional validated antigens.

In parallel, the project will develop a comprehensive business plan and engage with CMC, clinical & regulatory experts to define a product development strategy and a clear roadmap that de‑risks the transition into first‑in‑human studies of the lead candidate.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Amsterdam UmcAmsterdamNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI